The noradrenergic symptom cluster: clinical expression and neuropharmacology
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The noradrenergic symptom cluster: clinical expression and neuropharmacology Pierre Blier1, Mike Briley21Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada; 2NeuroBiz Consulting and Communication, Castres,FranceAbstract: Signs and symptoms of depression can be linked to one or more monoaminergic systems, specifically the norepinephrine (NE), the dopamine (DA), and the serotonin (5-HT) systems. In particular, the modulation of energy, vigilance, and arousal can be directly linked to the NE system. There is, however, a great deal of overlap in the modulation of the symptoms of depression between these monoaminergic systems. There are considerable reciprocal interactions between the NE, DA, and the 5-HT systems. When using a selective serotonin reuptake inhibitor (SSRI), for example, 5-HT transmission is enhanced, but at the same time there is a dampening of the activity of NE and DA neurons through inhibitory 5-HT2A and 5-HT2C receptors, respectively. This could explain the residual symptoms of fatigue, lack of energy, and anhedonia, often seen after patients present an overall positive response to a SSRI. Using a dual 5-HT and NE reuptake inhibitor (SNRI), such as milnacipran, would result in an additional increase in NE activity. Futhermore, inhibiting NE reuptake increases DA availability in the frontal cortex since DA is mainly cleared by the NE transporters in several brain regions. A risk inherent in increased NE activity is that of provoking anxiety. This is avoided however by the attenuation of the phasic reactivity of the firing of NE neurons through prolonged administration of SSRI and SNRI.Keywords: norepinephrine, dopamine, serotonin, residual symptoms, norepinephrine paradox
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · cited 1×
“The selective NE uptake inhibitors, reboxetine and atomoxetine, which have no affinity with the DA transporter, have been shown to increase extracellular DA levels as well as NE levels in the prefrontal cortex, but not in the nucleus accumbens.(22,23) The inhibition of the NE transporter by milnacipran therefore resul…”
BackgroundNeurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Conradi, H. J., Ormel, J., & de Jonge, P. (2011) · Psychological Medicine · doi:10.1017/s0033291710001911 · Cited by 515 · cited 1×
“The nature of the residual symptoms can vary depending on the nature of the initial depression and antidepressant used(4) but in general, fatigue (both mental and physical), concentration difficulties, decreased interest or pleasure, cognitive impairment, and anxiety are among the most common residual symptoms.(3,5) F…”
BackgroundResidual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 1×
“For example, in a study of 215 patients with major depressive disorder who received fluoxetine for 8 weeks, 108 were found to be in remission (HAMD # 7).(6) Of these, however, only 18% had no threshold or subthreshold symptoms of major depression, while 26% had one residual symptom, and over half (57%) still had 2 or…”
BackgroundNutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366 · cited 2×
“In addition to the reduced quality of life this causes, relapse rates are 3 to 6 times higher in patients with residual symptoms.(2,3)”
BackgroundThe brainstem noradrenergic systems in stress, anxiety and depression
Itoi, K., & Sugimoto, N. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.01988.x · Cited by 207
Haddjeri, N., De Montigny, C., & Blier, P. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0700968 · Cited by 164 · cited 1×
“This has been shown in animal studies where brain 5-HT levels were reduced by administration of the 5-HT synthesis inhibitor, p-chlorophenylalanine(7) or by lesion of the raphe nucleus using the specific 5-HT neuron toxin, 5,7-dihydroxytryptamine (5,7-DHT).(8) In both cases removal of the serotonergic influence on the…”
MethodSelf-citationClinical Evidence and Potential Neurobiological Underpinnings of Unresolved Symptoms of Depression
Trivedi, M. H., Hollander, E., Nutt, D., & Blier, P. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0211 · Cited by 153
Self-citationHains, A. B., & Arnsten, A. F. T. (2008) · Learning & Memory · doi:10.1101/lm.921708 · Cited by 127 · cited 1×
“26 Very low levels of NE (and DA) transmission result in cognitive impairment, inattention, and drowsiness.”
Herrera-Guzmán, I., Gudayol-Ferré, E., Herrera-Abarca, J. E., Herrera-Guzmán, D., Montelongo-Pedraza, P., Padrós Blázquez, F., Peró-Cebollero, M., & Guàrdia-Olmos, J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.10.009 · Cited by 94 · cited 1×
“24”
Cited by
The role of sleep in emotional brain function
Goldstein, A. N., & Walker, M. P. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153716 · Cited by 1,052
“…the greater duration and/or intensity of REM sleep often reported in major depression may provide a mechanistic explanation for the abnormally low levels of noradrenaline commonly observed with this condition (Blier & Briley 2011, El Mansari et al 2010, Hamon & Blier 2013, Ordway et al 2003).”
BackgroundThe neuroimmune basis of fatigue
Dantzer, R., Heijnen, C. J., Kavelaars, A., Laye, S., & Capuron, L. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.10.003 · Cited by 346
Auclair, A. L., Martel, J. C., Assié, M. B., Bardin, L., Heusler, P., Cussac, D., Marien, M., Newman-Tancredi, A., O'Connor, J. A., & Depoortère, R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.024 · Cited by 263
Emotional blunting with antidepressant treatments: A survey among depressed patients
Goodwin, G. M., Price, J., De Bodinat, C., & Laredo, J. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.05.048 · Cited by 202
Manta, S., El Mansari, M., Debonnel, G., & Blier, P. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000387 · Cited by 192
“Furthermore, this negative impact of SSRIS on the NE system could be in part responsible for residual symptoms such as fatigue, concentration difficulties, and cognitive impairment in patients receiving such treatment (Blier & Briley, 2011 ; Kasper et al. 2011).”
BackgroundSelf-citationBrubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s501207 · Cited by 7
Metadata
- Authors
- Briley, M., & Blier, P.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2011-06
- Volume
- 7
- Issue
- Suppl 1
- Pages
- 15
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2157860685
- Cited by
- 63
- References
- 11
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.